[go: up one dir, main page]

SG11201803606XA - Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia - Google Patents

Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia

Info

Publication number
SG11201803606XA
SG11201803606XA SG11201803606XA SG11201803606XA SG11201803606XA SG 11201803606X A SG11201803606X A SG 11201803606XA SG 11201803606X A SG11201803606X A SG 11201803606XA SG 11201803606X A SG11201803606X A SG 11201803606XA SG 11201803606X A SG11201803606X A SG 11201803606XA
Authority
SG
Singapore
Prior art keywords
presbyopia
molecules containing
containing peg
bifunctional molecules
cataracts
Prior art date
Application number
SG11201803606XA
Other languages
English (en)
Inventor
Murugappan Muthukumar
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of SG11201803606XA publication Critical patent/SG11201803606XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eyeglasses (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
SG11201803606XA 2015-11-13 2016-11-11 Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia SG11201803606XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254863P 2015-11-13 2015-11-13
PCT/US2016/061490 WO2017083619A1 (en) 2015-11-13 2016-11-11 Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia

Publications (1)

Publication Number Publication Date
SG11201803606XA true SG11201803606XA (en) 2018-05-30

Family

ID=57421950

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803606XA SG11201803606XA (en) 2015-11-13 2016-11-11 Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia

Country Status (18)

Country Link
US (1) US10736863B2 (es)
EP (1) EP3373921B1 (es)
JP (1) JP6794444B2 (es)
KR (1) KR102696354B1 (es)
CN (1) CN108348494A (es)
AU (1) AU2016354479B2 (es)
CA (1) CA3004585A1 (es)
CL (1) CL2018001282A1 (es)
CR (1) CR20180294A (es)
EA (1) EA035402B1 (es)
ES (1) ES2745291T3 (es)
IL (1) IL259027B (es)
MX (1) MX376641B (es)
PE (1) PE20181070A1 (es)
SA (1) SA518391553B1 (es)
SG (1) SG11201803606XA (es)
WO (1) WO2017083619A1 (es)
ZA (1) ZA201802978B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968239B1 (en) 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
ES2745291T3 (es) 2015-11-13 2020-02-28 Univ Massachusetts Moléculas difuncionales que contienen PEG para su uso en la inhibición de cataratas y presbicia
US10220012B2 (en) 2016-06-03 2019-03-05 Joerg H. KRUMEICH Solution for ophthalmology
TWI798452B (zh) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 隱形眼鏡產品
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351826A (en) 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4526789A (en) 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4665089A (en) 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US4620979A (en) 1985-08-02 1986-11-04 Schachar Ronald A Ophthalmological irrigating solution containing ascorbate
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
CA1269327A (en) 1986-04-24 1990-05-22 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US5055291A (en) 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4808182A (en) 1986-11-26 1989-02-28 Nestle, S.A. Deswelled, hydrogel intraocular lenses
US5338545A (en) 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5091421A (en) 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
DE3906311A1 (de) 1989-02-28 1990-08-30 Adatomed Pharma & Med Behandlungsystem zur verhinderung von nachstarbildung nach einer kataraktoperation
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
ATE138914T1 (de) 1990-12-10 1996-06-15 Bio Physio Pharmaceutical Rese Indeno-d-pyrimidonverbindungen zur verwendung in der medizin
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
HUT71250A (en) 1992-05-20 1995-11-28 Senju Pharma Co Remedy for cataract and production thereof
US5375611A (en) 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
CN1045383C (zh) 1993-04-07 1999-10-06 王慧康 用于治疗老年性白内障的药物组合物
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
WO1995013827A1 (en) 1993-11-19 1995-05-26 The University Of Sydney A method for preventing or controlling cataract
US5516534A (en) 1993-11-26 1996-05-14 Rensselaer Polytechnic Institute Composition and method for reducing structural defects
US5591773A (en) 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
EP0712635B1 (en) 1994-05-13 2003-05-02 Kuraray Co., Ltd. Medical polymer gel
DE69629230D1 (de) 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP3599848B2 (ja) 1995-09-11 2004-12-08 株式会社メニコン 含水性軟質眼用レンズ用材料、それからなる含水性軟質眼用レンズ用成形体、ならびにそれからなる含水性軟質眼用レンズおよびその製法
EP0781777A1 (en) 1995-12-28 1997-07-02 Menicon Co., Ltd. Silicon-containing compound and ocular lens material
EP0816398B1 (en) 1996-06-28 2002-08-14 Ube Industries, Ltd. Process for producing polybutadiene
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
JPH10339857A (ja) 1997-06-05 1998-12-22 Menicon Co Ltd 薬剤徐放性コンタクトレンズの製法およびそれによってえられた薬剤徐放性コンタクトレンズ
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
EP1149909A1 (en) 2000-04-28 2001-10-31 Boehringer Mannheim Gmbh Methods for regulating protein conformation using molecular chaperones
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2389917A1 (en) 1999-11-04 2001-05-10 Kazunori Kataoka A polymer micelle as monolayer or layer-laminated surface
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
US20020042043A1 (en) * 2000-05-31 2002-04-11 Adonis Stassinopoulos Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
HU230002B1 (en) 2000-12-15 2015-04-28 Sigma Tau Ind Farmaceuti Use of l-carnitine for preparation of compositions for stabilizing the proteins
US6958224B2 (en) 2001-03-28 2005-10-25 Council Of Scientific And Industrial Research Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
US20030020870A1 (en) 2001-06-27 2003-01-30 Zms, Llc Biomedical molding materials from semi-solid precursors
JP4838968B2 (ja) * 2001-09-28 2011-12-14 参天製薬株式会社 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
EP1437143A4 (en) * 2001-09-28 2007-05-09 Santen Pharmaceutical Co Ltd INJECTIONS FOR EYE TISSUE WITH POLYETHYLENE GLYCOL-BOUNDED MEDICINAL PRODUCT
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
AU2003226059A1 (en) 2002-04-10 2003-10-27 The Regents Of The University Of California Biodegradable peg-based polymer formulations in ocular applications
US6924154B2 (en) 2002-08-20 2005-08-02 Quest Diagnostics Investments Incorporated Hydrophilic chemilumescent acridinium labeling reagents
JP2004161731A (ja) 2002-09-25 2004-06-10 Nof Corp 生体関連物質用固定化剤
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
CN1621091A (zh) 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
US20090247604A1 (en) 2004-02-05 2009-10-01 Intradigm Corporation RNAi Therapeutics for Treatment of Eye Neovascularization Diseases
US7887847B2 (en) 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
WO2005117987A1 (en) 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
CA2583231A1 (en) * 2004-11-04 2006-05-18 University Of Washington Compositions and methods for treatment of protein misfolding and protein aggregation diseases
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CN1660920A (zh) 2005-02-01 2005-08-31 华东理工大学 末端连接ω－氨基酸的聚乙二醇酸或活性酯及制法和应用
WO2006091796A2 (en) 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
DE102005041570A1 (de) 2005-09-01 2007-03-22 Celares Gmbh Hoch verzweigte Reagenzien zur Modifaktion von Biopharmazeutika, deren Herstellung und Anwendung
US7832875B2 (en) 2005-09-29 2010-11-16 Virtek Vision International Inc. Modulated diode pumped microchip laser projector
US20080094573A1 (en) 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US20070275098A1 (en) 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2009029991A1 (en) 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
CN101903045B (zh) 2007-10-19 2013-03-13 株式会社·R-技术上野 用于治疗白内障的药物组合物
KR20100000203A (ko) 2008-06-24 2010-01-06 인하대학교 산학협력단 금나노입자를 이용한 표적지향형 항암약물전달체
WO2010002563A1 (en) 2008-06-30 2010-01-07 Johnson & Johnson Vision Care, Inc. Methods and ophtalmic devices used in the treatment of ocular allergies
MY155612A (en) * 2008-07-14 2015-11-13 Biocon Ltd A method of synthesizing a substantially monodispersed mixture of oligomers
WO2010065024A1 (en) 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
US8758802B2 (en) 2009-12-14 2014-06-24 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2011133566A2 (en) 2010-04-19 2011-10-27 University Of Louisville Research Foundation, Inc. Repairing bruch's membrane with hydrogels
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN102172410B (zh) 2011-01-14 2013-08-07 华南理工大学 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
EP2691973B1 (en) 2011-03-31 2019-05-08 DH Technologies Development Pte. Ltd. Composition, method, and kit for calibrating a mass spectrometer
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
WO2012167081A1 (en) * 2011-06-03 2012-12-06 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
SG11201400293UA (en) 2011-09-04 2014-08-28 Glytech Inc Glycosylated polypeptide and drug composition containing said polypeptide
KR20140103099A (ko) 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 예방 및 치료
CN102579353B (zh) 2012-03-30 2013-12-04 吉林大学 叶酸靶向的抗癌药物peg修饰的脂质体及制备方法
SG11201500288QA (en) * 2012-07-17 2015-02-27 Univ Michigan Inhibitors of alpha-crystallin aggregation for the treatment for cataract
MX370543B (es) 2012-10-11 2019-12-17 Ascendis Pharma Ophthalmology Div A/S Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
US20150291672A1 (en) 2012-11-01 2015-10-15 The Johns Hopkins University Contact Lens Surface Modification with Hyaluronic Acid (HA) Binding Peptide for HA Accumulation and Retention
EP2968239B1 (en) 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2014171842A1 (en) * 2013-04-19 2014-10-23 Living Cell Technologies New Zealand Limited Biocompatible encapsulation system
CN113274506A (zh) 2013-12-05 2021-08-20 念·吴 聚合物-碳水化合物的缀合物的药物转递技术
ES2745291T3 (es) 2015-11-13 2020-02-28 Univ Massachusetts Moléculas difuncionales que contienen PEG para su uso en la inhibición de cataratas y presbicia

Also Published As

Publication number Publication date
EA035402B1 (ru) 2020-06-08
PE20181070A1 (es) 2018-07-04
KR20180083378A (ko) 2018-07-20
CA3004585A1 (en) 2017-05-18
IL259027A (en) 2018-06-28
KR102696354B1 (ko) 2024-08-19
MX2018005903A (es) 2019-04-04
MX376641B (es) 2025-03-07
EP3373921A1 (en) 2018-09-19
US10736863B2 (en) 2020-08-11
SA518391553B1 (ar) 2021-03-01
CN108348494A (zh) 2018-07-31
CL2018001282A1 (es) 2018-11-16
ZA201802978B (en) 2019-07-31
WO2017083619A1 (en) 2017-05-18
CR20180294A (es) 2018-08-10
ES2745291T3 (es) 2020-02-28
IL259027B (en) 2021-05-31
AU2016354479A1 (en) 2018-05-24
US20170135972A1 (en) 2017-05-18
AU2016354479B2 (en) 2021-10-07
JP6794444B2 (ja) 2020-12-02
BR112018009582A2 (pt) 2018-11-06
EP3373921B1 (en) 2019-08-28
EA201891161A1 (ru) 2018-10-31
JP2018536659A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
ZA201806382B (en) Liquid filter arrangement and methods
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
SG11201608179PA (en) Fast viscoacoustic and viscoelastic full-wavefield inversion
HUE050173T2 (hu) Triciklusos vegyületek, és alkalmazásuk a gyógyászatban
PL3228648T3 (pl) Kopoliwęglan i zawierające go kompozycje
SI3215601T1 (sl) Postopki za transdukcijo in obdelavo celic
ZA201607874B (en) Modified vinylamine containing polymers and their use in papermaking
SG10202011033QA (en) Phthalocyanine dye conjugates and their storage
GB201511382D0 (en) Novel compounds and their use in therapy
PL3048127T3 (pl) Kopoliwęglan i zawierająca go kompozycja
ZA201802978B (en) Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia
PL3194656T3 (pl) Uchwyt listwy uszczelniającej oraz jego zastosowanie
PL3067379T3 (pl) Kopoliwęglan i zawierająca go kompozycja
PL3122865T3 (pl) Zobojętnione koncentraty octowe i ciekłe mieszanki spożywcze zawierające wspomniane zobojętnione koncentraty octowe
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
ZA201801302B (en) Novel microorganisms and their use in agriculture
PL3406258T3 (pl) Lek do stosowania w leczeniu dny moczanowej
PL3050908T3 (pl) Kopoliwęglan i zawierająca go kompozycja
PT2944309T (pt) Utilização de palmitoiletanolamida em combinação com opióides
SG11201604933RA (en) Static elimination articles and methods for their use
PL3050909T3 (pl) Kopoliwęglan i obejmująca go kompozycja
GB201522904D0 (en) Liquid molecule refinement and containment device
GB201411967D0 (en) Imorovements in level monitors for substances within vessels
EP3592332C0 (fr) Nouvelle solution visco-élastique et son utilisation en rhumatologie
SG11201606989XA (en) Catechin-free tea water and composition containing same